Novartis migraine drug not cost effective - UK price watchdog [Reuters]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Reuters
Novartis migraine drug not cost effective - UK price watchdog | Reuters 2 Min Read ZURICH (Reuters) - Britain’s drug price watchdog on Thursday rejected Novartis’s migraine drug Aimovig for now, concluding in a draft decision that the medicine was not a cost-effective use of National Health Service resources. Novartis, with exclusive rights to the drug in Europe while cooperating with Amgen in the United States, said it was “disappointed” in the National Institute for Health and Care Excellence’s (NICE) conclusion. It marks the second time within months the UK agency has rejected reimbursement for a key medicine from the Swiss drugmaker. Novartis, whose U.K. price for Aimovig is about 5,000 pounds ($6,374) annually but which was offering discounts, is counting on the medicine to be a foundation of its neuroscience business and a key part of boosting revenue as older medicines lose patent protection. Some analysts see 2022 sales nearing $1 billion, according to Refinitiv. While NICE sa
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Why Amgen (AMGN) Outpaced the Stock Market Today [Yahoo! Finance]Yahoo! Finance
- 3 Generic Drug Stocks to Watch Amid Challenging Market Prospects [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at UBS Group AG from $314.00 to $284.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen (AMGN) Suffers a Larger Drop Than the General Market: Key Insights [Yahoo! Finance]Yahoo! Finance
- Amgen Inc. (NASDAQ: AMGN) had its price target lowered by analysts at TD Cowen from $370.00 to $360.00. They now have a "buy" rating on the stock.MarketBeat
AMGN
Earnings
- 2/6/24 - Beat
AMGN
Sec Filings
- 4/17/24 - Form DEFA14A
- 4/17/24 - Form DEF
- 4/10/24 - Form ARS
- AMGN's page on the SEC website